CL2004000647A1 - Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am - Google Patents

Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am

Info

Publication number
CL2004000647A1
CL2004000647A1 CL200400647A CL2004000647A CL2004000647A1 CL 2004000647 A1 CL2004000647 A1 CL 2004000647A1 CL 200400647 A CL200400647 A CL 200400647A CL 2004000647 A CL2004000647 A CL 2004000647A CL 2004000647 A1 CL2004000647 A1 CL 2004000647A1
Authority
CL
Chile
Prior art keywords
inhibitors
amiloid
beta
angiopatia
heterocicles
Prior art date
Application number
CL200400647A
Other languages
English (en)
Spanish (es)
Inventor
Anthony Frank Resnick Ly Kreft
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CL2004000647A1 publication Critical patent/CL2004000647A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL200400647A 2003-03-31 2004-03-26 Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am CL2004000647A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45922803P 2003-03-31 2003-03-31

Publications (1)

Publication Number Publication Date
CL2004000647A1 true CL2004000647A1 (es) 2005-02-04

Family

ID=33299665

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400647A CL2004000647A1 (es) 2003-03-31 2004-03-26 Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am

Country Status (22)

Country Link
US (3) US7300951B2 (https=)
EP (1) EP1608638A1 (https=)
JP (1) JP2006522126A (https=)
KR (1) KR20060002908A (https=)
CN (2) CN1780829B (https=)
AR (1) AR043940A1 (https=)
AU (1) AU2004230844B2 (https=)
BR (1) BRPI0408962A (https=)
CA (1) CA2517155A1 (https=)
CL (1) CL2004000647A1 (https=)
CO (1) CO5640049A2 (https=)
CR (1) CR7951A (https=)
EC (1) ECSP056128A (https=)
MX (1) MXPA05010368A (https=)
NO (1) NO20054263L (https=)
NZ (1) NZ542468A (https=)
RU (1) RU2342374C2 (https=)
SG (1) SG167669A1 (https=)
TW (1) TWI336698B (https=)
UA (1) UA82093C2 (https=)
WO (1) WO2004092155A1 (https=)
ZA (1) ZA200507896B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517892A (ja) * 2000-12-13 2004-06-17 ワイス β−アミロイド産生の複素環スルホンアミド阻害剤
CA2471099C (en) * 2001-12-20 2011-04-12 Bristol-Myers Squibb Company .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors
KR20050010882A (ko) * 2002-06-11 2005-01-28 와이어쓰 베타 아밀로이드 생산의 치환 페닐술폰아미드 저해제
KR20060002908A (ko) * 2003-03-31 2006-01-09 와이어쓰 베타 아밀로이드 생산 억제제인 플루오로- 및트리플루오로알킬-함유 헤테로사이클릭 설폰아미드 및 이의유도체
DE602005016775D1 (de) * 2004-01-16 2009-11-05 Wyeth Corp Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
AR059517A1 (es) * 2006-02-17 2008-04-09 Wyeth Corp N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo
EP1984321A1 (en) * 2006-02-17 2008-10-29 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
CN101472877A (zh) * 2006-04-21 2009-07-01 惠氏公司 制备手性纯氨基醇中间体、其衍生物及其用途
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
US7550629B2 (en) * 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
JP2010509235A (ja) * 2006-11-03 2010-03-25 ノースウェスタン ユニバーシティ 多発性硬化症の治療
TW200911778A (en) * 2007-07-16 2009-03-16 Wyeth Corp Process for the preparation of trifluoroalkyl-phenyl and heterocyclic sulfonamides
JP2010533723A (ja) * 2007-07-16 2010-10-28 ワイス・エルエルシー βアミロイド生成の阻害剤
PA8789801A1 (es) * 2007-07-16 2009-02-09 Wyeth Corp Procesos e intermadiarios para la preparacion de compuestos de silfonamida heterocíclica
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
TW200934482A (en) * 2008-01-11 2009-08-16 Wyeth Corp Compositions containing o-sulfate and o-phosphate containing aryl sulfonamide derivatives useful as β -amyloid inhibitors
WO2009137657A1 (en) * 2008-05-08 2009-11-12 Bristol-Myers Squibb Company 2-aryl glycinamide derivatives
US8992783B2 (en) 2008-09-05 2015-03-31 Max-Planck-Gessellschaft zur förderung der Wissenschaften e.V. Process for enantioseparation of chiral systems with compound formation using two subsequent crystallization steps
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US20110071199A1 (en) * 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
US7977362B2 (en) * 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
WO2011084503A1 (en) * 2009-12-16 2011-07-14 North Carolina Central University Phenoxy thiophene sulfonamides and their use in the treatment of neurodegenerative diseases
US9223209B2 (en) * 2010-02-19 2015-12-29 International Business Machines Corporation Sulfonamide-containing photoresist compositions and methods of use
US9223217B2 (en) 2010-02-19 2015-12-29 International Business Machines Corporation Sulfonamide-containing topcoat and photoresist additive compositions and methods of use
WO2011112858A1 (en) * 2010-03-10 2011-09-15 North Carolina Central University Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
US20150209367A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye & Ear Infirmary Treating Hearing Loss
JP6319912B2 (ja) 2013-04-19 2018-05-09 国立大学法人 岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
US11370823B2 (en) 2014-10-29 2022-06-28 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
JP6840774B2 (ja) 2016-05-16 2021-03-10 ザ ジェネラル ホスピタル コーポレイション 肺上皮エンジニアリングにおけるヒト気道幹細胞
WO2019148067A1 (en) 2018-01-26 2019-08-01 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
EP4299062A1 (en) 2022-06-30 2024-01-03 Vilnius University Inhibition of protein amyloid aggregation using fluorinated benzenesulfonamides

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0510700A3 (en) 1991-04-26 1992-12-16 Takeda Chemical Industries, Ltd. Azole compounds, their production and use
GB9110722D0 (en) 1991-05-17 1991-07-10 Fujisawa Pharmaceutical Co Amine derivatives
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
NZ264143A (en) 1993-08-09 1996-11-26 Lilly Co Eli Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
US5519040A (en) 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
ATE377006T1 (de) 1995-11-28 2007-11-15 Cephalon Inc Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer
JP2000515153A (ja) 1996-07-22 2000-11-14 モンサント カンパニー チオールスルホンアミド メタロプロテアーゼインヒビター
US5703129A (en) 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
US5985930A (en) 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
TR199901132T2 (xx) 1996-11-22 1999-08-23 Elan Pharmaceuticals, Inc. N-(aril/heteoaril) amino asit t�revleri, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler.
DE19650196A1 (de) 1996-12-04 1998-06-10 Bayer Ag Thienylsulfonylamino(thio)carbonylverbindungen
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
NZ514453A (en) 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
AU765203B2 (en) 1999-04-19 2003-09-11 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1222176A1 (en) 1999-10-08 2002-07-17 Bristol-Myers Squibb Pharma Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION
WO2001070677A1 (en) 2000-03-20 2001-09-27 Merck Sharp & Dohme Limited Sulphonamido-substituted bridged bicycloalkyl derivatives
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
JP2004517892A (ja) 2000-12-13 2004-06-17 ワイス β−アミロイド産生の複素環スルホンアミド阻害剤
WO2003050062A2 (en) 2001-12-11 2003-06-19 Wyeth PRODUCTION OF CHIRALLY PURE α-AMINO ACIDS ADN N-SULFONYL α-AMINO ACIDS
BR0214863A (pt) 2001-12-11 2004-12-14 Wyeth Corp Processo para a sìntese de beta-aminoálcoois quiralmente puros
KR20050010882A (ko) 2002-06-11 2005-01-28 와이어쓰 베타 아밀로이드 생산의 치환 페닐술폰아미드 저해제
KR20060002908A (ko) 2003-03-31 2006-01-09 와이어쓰 베타 아밀로이드 생산 억제제인 플루오로- 및트리플루오로알킬-함유 헤테로사이클릭 설폰아미드 및 이의유도체
DE602005016775D1 (de) 2004-01-16 2009-11-05 Wyeth Corp Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
AR059517A1 (es) * 2006-02-17 2008-04-09 Wyeth Corp N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo
EP1984321A1 (en) * 2006-02-17 2008-10-29 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
CN101472877A (zh) * 2006-04-21 2009-07-01 惠氏公司 制备手性纯氨基醇中间体、其衍生物及其用途
US7550629B2 (en) * 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
JP2010533723A (ja) * 2007-07-16 2010-10-28 ワイス・エルエルシー βアミロイド生成の阻害剤
PA8789801A1 (es) * 2007-07-16 2009-02-09 Wyeth Corp Procesos e intermadiarios para la preparacion de compuestos de silfonamida heterocíclica
TW200911778A (en) * 2007-07-16 2009-03-16 Wyeth Corp Process for the preparation of trifluoroalkyl-phenyl and heterocyclic sulfonamides

Also Published As

Publication number Publication date
UA82093C2 (uk) 2008-03-11
CR7951A (es) 2008-10-29
US7547725B2 (en) 2009-06-16
US7858658B2 (en) 2010-12-28
AU2004230844B2 (en) 2010-12-09
CA2517155A1 (en) 2004-10-28
AU2004230844A1 (en) 2004-10-28
US7300951B2 (en) 2007-11-27
NZ542468A (en) 2009-01-31
ECSP056128A (es) 2006-03-01
KR20060002908A (ko) 2006-01-09
CN101274926A (zh) 2008-10-01
NO20054263D0 (no) 2005-09-15
WO2004092155A1 (en) 2004-10-28
ZA200507896B (en) 2007-03-28
AR043940A1 (es) 2005-08-17
RU2342374C2 (ru) 2008-12-27
SG167669A1 (en) 2011-01-28
CN1780829A (zh) 2006-05-31
TW200504047A (en) 2005-02-01
US20090227667A1 (en) 2009-09-10
RU2005133434A (ru) 2006-07-10
MXPA05010368A (es) 2005-11-17
TWI336698B (en) 2011-02-01
US20070254929A1 (en) 2007-11-01
US20040198778A1 (en) 2004-10-07
BRPI0408962A (pt) 2006-04-04
NO20054263L (no) 2005-12-14
CN1780829B (zh) 2010-12-29
JP2006522126A (ja) 2006-09-28
EP1608638A1 (en) 2005-12-28
CO5640049A2 (es) 2006-05-31

Similar Documents

Publication Publication Date Title
CL2004000647A1 (es) Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
GT200500237A (es) Derivados de pirimidina
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
PA8583401A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
DE60335743D1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
DOP2006000084A (es) Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos compuestos, metodos de preparacion y usos de los mismos
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
PA8604201A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
SV2004001555A (es) Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
EA200801011A1 (ru) Производные пиразина как модуляторы натриевых каналов для лечения боли
EA200600996A1 (ru) Композиция для полезного воздействия на кожу с использованием ключевых промежуточных продуктов клеточного метаболизма
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos